{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:01:20Z","timestamp":1784649680085,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.xcrm.2026.102922","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:46:52Z","timestamp":1784040412000},"page":"102922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers"],"prefix":"10.1016","volume":"7","author":[{"given":"Meijie","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry T.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam T.","family":"Cheuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siteng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor T.","family":"Ojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor G.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Milewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Yean","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Chao","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avani","family":"Kelekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumili","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunkai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Asikur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M. Naseer","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatobi","family":"Arisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam K.","family":"Sharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe Weaver","family":"Ohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila","family":"Szabova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Difilippantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borys","family":"Shor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Nathan","family":"Tumey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun S.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5858-0488","authenticated-orcid":false,"given":"Javed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102922_bib1","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.20.03060","article-title":"Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium","volume":"39","author":"Shern","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102922_bib2","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/jcm10071416","article-title":"Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force","volume":"10","author":"Pacenta","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.xcrm.2026.102922_bib3","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/cncr.32205","article-title":"Optimal dosing of cyclophosphamide in rhabdomyosarcoma: It's complicated","volume":"125","author":"Lucas","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2026.102922_bib4","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1200\/JCO.2018.77.9694","article-title":"Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group","volume":"36","author":"Hawkins","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102922_bib5","article-title":"Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma","volume":"4","author":"Tian","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102922_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/89044","article-title":"Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks","volume":"7","author":"Khan","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102922_bib7","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1158\/2159-8290.CD-16-1297","article-title":"PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability","volume":"7","author":"Gryder","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102922_bib8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-13-0639","article-title":"Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors","volume":"4","author":"Shern","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102922_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110047","article-title":"Immuno-transcriptomic profiling of extracranial pediatric solid malignancies","volume":"37","author":"Brohl","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102922_bib10","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102922_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2026.102922_bib12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/14737140.2024.2344647","article-title":"Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma","volume":"24","author":"Tacchetti","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.xcrm.2026.102922_bib13","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102922_bib14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1021\/acs.bioconjchem.1c00124","article-title":"Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers","volume":"32","author":"Miller","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.xcrm.2026.102922_bib15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102922_bib16","doi-asserted-by":"crossref","first-page":"25505","DOI":"10.1021\/acs.jmedchem.5c02681","article-title":"Legumain-Cleavable Top1i Antibody-Drug Conjugates without Self-Immolative Spacers Demonstrate Potent Antitumor Activity","volume":"68","author":"Ojo","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.102922_bib17","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102922_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1158\/1535-7163.MCT-23-0359","article-title":"Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates","volume":"23","author":"Schmitt","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2026.102922_bib19","doi-asserted-by":"crossref","first-page":"20303","DOI":"10.1074\/jbc.M300198200","article-title":"Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes","volume":"278","author":"Furuta","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.102922_bib20","doi-asserted-by":"crossref","first-page":"21767","DOI":"10.1074\/jbc.M300229200","article-title":"Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents","volume":"278","author":"Xiao","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.102922_bib21","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102922_bib22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3390\/pharmaceutics15041132","article-title":"Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes","volume":"15","author":"Chang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xcrm.2026.102922_bib23","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1038\/s41388-017-0122-y","article-title":"Functional screening of FGFR4-driven tumorigenesis identifies PI3K\/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma","volume":"37","author":"McKinnon","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2026.102922_bib24","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1038\/s41467-024-50251-x","article-title":"CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma","volume":"15","author":"Tian","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102922_bib25","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102922_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/bc025536j","article-title":"Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity","volume":"13","author":"Dubowchik","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.xcrm.2026.102922_bib27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102922_bib28","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102922_bib29","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2009.26.2071","article-title":"Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer","volume":"28","author":"Krop","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102922_bib30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1208\/s12248-015-9790-0","article-title":"Antibody Drug Conjugates: Nonclinical Safety Considerations","volume":"17","author":"Hinrichs","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.xcrm.2026.102922_bib31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/00498254.2024.2352051","article-title":"A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers","volume":"54","author":"Gray","year":"2024","journal-title":"Xenobiotica"},{"key":"10.1016\/j.xcrm.2026.102922_bib32","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.xcrm.2026.102922_bib33","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102922_bib34","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102922_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70439","article-title":"Fibroblast Growth Factor Receptor 4 Promotes Triple-Negative Breast Cancer Progression via Regulating Fatty Acid Metabolism Through the AKT\/RYR2 Signaling","volume":"13","author":"Ye","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.xcrm.2026.102922_bib36","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1158\/1078-0432.CCR-08-0890","article-title":"Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation","volume":"15","author":"Roidl","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102922_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1677\/ERC-07-0080","article-title":"Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer","volume":"15","author":"Meijer","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.xcrm.2026.102922_bib38","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ijc.35271","article-title":"Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4-overexpressing breast cancer cells","volume":"156","author":"Cheng","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102922_bib39","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/s41588-019-0534-4","article-title":"Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma","volume":"51","author":"Gryder","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2026.102922_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.116746","article-title":"Development and optimization of a high-throughput LC-MS\/MS method for the simultaneous determination of Exatecan and its Cathepsin B-sensitive prodrug, and ARV-825 in rat plasma: Application to pharmacokinetic study","volume":"258","author":"Xu","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.xcrm.2026.102922_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4855","article-title":"Liquid chromatography-high resolution mass spectrometric method for the quantification of monomethyl auristatin E (MMAE) and its preclinical pharmacokinetics","volume":"34","author":"Lee","year":"2020","journal-title":"Biomed. Chromatogr."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:02:40Z","timestamp":1784646160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126003393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666379126003393"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102922","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102922"}}